Quantifying the Strength of Heterointeractions Among Receptor Tyrosine Kinases from Different Subfamilies: Implications for Cell Signaling

Overview

Journal J Biol Chem

Specialty Biochemistry

Date 2020 May 30

PMID 32467228

Citations 18

Authors

Michael D Paul

Hana N Grubb

Kalina Hristova

Affiliations

Soon will be listed here.

Abstract

Receptor tyrosine kinases (RTKs) are single-pass membrane proteins that control vital cell processes such as cell growth, survival, and differentiation. There is a growing body of evidence that RTKs from different subfamilies can interact and that these diverse interactions can have important biological consequences. However, these heterointeractions are often ignored, and their strengths are unknown. In this work, we studied the heterointeractions of nine RTK pairs, epidermal growth factor receptor (EGFR)-EPH receptor A2 (EPHA2), EGFR-vascular endothelial growth factor receptor 2 (VEGFR2), EPHA2-VEGFR2, EPHA2-fibroblast growth factor receptor 1 (FGFR1), EPHA2-FGFR2, EPHA2-FGFR3, VEGFR2-FGFR1, VEGFR2-FGFR2, and VEGFR2-FGFR3, using a FRET-based method. Surprisingly, we found that RTK heterodimerization and homodimerization strengths can be similar, underscoring the significance of RTK heterointeractions in signaling. We discuss how these heterointeractions can contribute to the complexity of RTK signal transduction, and we highlight the utility of quantitative FRET for probing multiple interactions in the plasma membrane.

Citing Articles

Phosphatidylinositol 4,5-bisphosphate drives the formation of EGFR and EphA2 complexes.

Kumar Singh P, Rybak J, Schuck R, Sahoo A, Buck M, Barrera F Sci Adv. 2024; 10(49):eadl0649.

PMID: 39630914 PMC: 11616708. DOI: 10.1126/sciadv.adl0649.

Targeting the EphA2 pathway: could it be the way for bone sarcomas?.

Giordano G, Tucciarello C, Merlini A, Cutrupi S, Pignochino Y Cell Commun Signal. 2024; 22(1):433.

PMID: 39252029 PMC: 11382444. DOI: 10.1186/s12964-024-01811-7.

Transmembrane helix interactions regulate oligomerization of the receptor tyrosine kinase EphA2.

Wirth D, Ozdemir E, Wimley W, Pasquale E, Hristova K J Biol Chem. 2024; 300(7):107441.

PMID: 38838777 PMC: 11263659. DOI: 10.1016/j.jbc.2024.107441.

Ligand bias underlies differential signaling of multiple FGFs via FGFR1.

Karl K, Del Piccolo N, Light T, Roy T, Dudeja P, Ursachi V Elife. 2024; 12.

PMID: 38568193 PMC: 10990489. DOI: 10.7554/eLife.88144.

Eph receptors and ephrins in cancer progression.

Pasquale E Nat Rev Cancer. 2023; 24(1):5-27.

PMID: 37996538 PMC: 11015936. DOI: 10.1038/s41568-023-00634-x.

References

Arteaga C, Engelman J . ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics. Cancer Cell. 2014; 25(3):282-303. PMC: 4018830. DOI: 10.1016/j.ccr.2014.02.025. View

Cheng C, Haasdijk R, Tempel D, den Dekker W, Chrifi I, Blonden L . PDGF-induced migration of vascular smooth muscle cells is inhibited by heme oxygenase-1 via VEGFR2 upregulation and subsequent assembly of inactive VEGFR2/PDGFRβ heterodimers. Arterioscler Thromb Vasc Biol. 2012; 32(5):1289-98. DOI: 10.1161/ATVBAHA.112.245530. View

Sarabipour S, Ballmer-Hofer K, Hristova K . VEGFR-2 conformational switch in response to ligand binding. Elife. 2016; 5:e13876. PMC: 4829425. DOI: 10.7554/eLife.13876. View

Schlessinger J . Signal transduction. Autoinhibition control. Science. 2003; 300(5620):750-2. DOI: 10.1126/science.1082024. View

King C, Stoneman M, Raicu V, Hristova K . Fully quantified spectral imaging reveals in vivo membrane protein interactions. Integr Biol (Camb). 2016; 8(2):216-29. PMC: 4755892. DOI: 10.1039/c5ib00202h. View

Baharuddin W, Yusoff A, Abdullah J, Osman Z, Ahmad F . Roles of EphA2 Receptor in Angiogenesis Signaling Pathway of Glioblastoma Multiforme. Malays J Med Sci. 2019; 25(6):22-27. PMC: 6422564. DOI: 10.21315/mjms2018.25.6.3. View

Singh D, Ahmed F, Paul M, Gedam M, Pasquale E, Hristova K . The SAM domain inhibits EphA2 interactions in the plasma membrane. Biochim Biophys Acta Mol Cell Res. 2016; 1864(1):31-38. PMC: 5148718. DOI: 10.1016/j.bbamcr.2016.10.011. View

Wu E, Palmer N, Tian Z, Moseman A, Galdzicki M, Wang X . Comprehensive dissection of PDGF-PDGFR signaling pathways in PDGFR genetically defined cells. PLoS One. 2008; 3(11):e3794. PMC: 2582946. DOI: 10.1371/journal.pone.0003794. View

Somanath P, Ciocea A, Byzova T . Integrin and growth factor receptor alliance in angiogenesis. Cell Biochem Biophys. 2008; 53(2):53-64. PMC: 2863046. DOI: 10.1007/s12013-008-9040-5. View

10.

Qiu C, Tarrant M, Boronina T, Longo P, Kavran J, Cole R . In vitro enzymatic characterization of near full length EGFR in activated and inhibited states. Biochemistry. 2009; 48(28):6624-32. PMC: 2747374. DOI: 10.1021/bi900755n. View

11.

Larsen A, Pedersen M, Stockhausen M, Grandal M, van Deurs B, Poulsen H . Activation of the EGFR gene target EphA2 inhibits epidermal growth factor-induced cancer cell motility. Mol Cancer Res. 2007; 5(3):283-93. DOI: 10.1158/1541-7786.MCR-06-0321. View

12.

Nicholson R, Gee J, Harper M . EGFR and cancer prognosis. Eur J Cancer. 2001; 37 Suppl 4:S9-15. DOI: 10.1016/s0959-8049(01)00231-3. View

13.

Boyd A, Bartlett P, Lackmann M . Therapeutic targeting of EPH receptors and their ligands. Nat Rev Drug Discov. 2014; 13(1):39-62. DOI: 10.1038/nrd4175. View

14.

Coon B, Baeyens N, Han J, Budatha M, Ross T, Fang J . Intramembrane binding of VE-cadherin to VEGFR2 and VEGFR3 assembles the endothelial mechanosensory complex. J Cell Biol. 2015; 208(7):975-86. PMC: 4384728. DOI: 10.1083/jcb.201408103. View

15.

Appert-Collin A, Hubert P, Cremel G, Bennasroune A . Role of ErbB Receptors in Cancer Cell Migration and Invasion. Front Pharmacol. 2015; 6:283. PMC: 4657385. DOI: 10.3389/fphar.2015.00283. View

16.

Ahmed F, Hristova K . Dimerization of the Trk receptors in the plasma membrane: effects of their cognate ligands. Biochem J. 2018; 475(22):3669-3685. PMC: 6918676. DOI: 10.1042/BCJ20180637. View

17.

Krejci P . The paradox of FGFR3 signaling in skeletal dysplasia: why chondrocytes growth arrest while other cells over proliferate. Mutat Res Rev Mutat Res. 2013; 759:40-8. DOI: 10.1016/j.mrrev.2013.11.001. View

18.

Paul M, Hristova K . The transition model of RTK activation: A quantitative framework for understanding RTK signaling and RTK modulator activity. Cytokine Growth Factor Rev. 2019; 49:23-31. PMC: 6898792. DOI: 10.1016/j.cytogfr.2019.10.004. View

19.

Singh B, Carpenter G, Coffey R . EGF receptor ligands: recent advances. F1000Res. 2016; 5. PMC: 5017282. DOI: 10.12688/f1000research.9025.1. View

20.

Singh D, Ahmed F, King C, Gupta N, Salotto M, Pasquale E . EphA2 Receptor Unliganded Dimers Suppress EphA2 Pro-tumorigenic Signaling. J Biol Chem. 2015; 290(45):27271-27279. PMC: 4646390. DOI: 10.1074/jbc.M115.676866. View